Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs, Haihe brings life-saving therapies to cancer patients worldwide.
As a new drug R&D company led by an academician of the Chinese Academy of Engineering, Haihe Biopharma is committed to the path of indigenous innovation. It also has a research and management team with a global perspective, and it is proactively mapping out the international development of innovative drugs.
Currently, seven of the 10 core products in the HaiHe's R&D pipeline have entered the clinical development stage, and four have obtained IND Implied License from the US FDA.
With support from top venture capitalists in life science and technology, HaiHe is accelerating the clinical development and commercialization of innovative products, and strives to provide patients with safe and effective drugs at the earliest possible time.
.png)
.png)
Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs, Haihe brings life-saving therapies to cancer patients worldwide.
July 2020
Haihe completed
Series B funding worth
1.2 billion yuan
July 2020
Haihe completed the reorganization of related group companies. Shanghai Haihe Pharmaceutical Research and Development Co Ltd acquired the stakes of Nuomaixi (Shanghai) Pharmaceutical Technology Co Ltd, and transferred the equities held by all shareholders to Shanghai Haihe Pharmaceutical Research and Development Co Ltd.
December 2019
Haihe established its US office
October 2019
Haihe’s Manufacturing Hub set foot in Taizhou Medical New & Hi-Tech Industrial Development Zone, with planned investment of 600 million yuan
September 2019
Haihe was recognized as Shanghai’s New & Hi-Tech Enterprise
April 2019
The investigational drug paclitaxel oral formulation RMX 3001's Phase III clinicaltrial, which enrolled patients with advanced gastric cancer, completed the first dosing
February 2019
Haihe completed Series A funding worth US$136.6 million
January 2019
The pivotal Phase IIb clinical trial of first-class innovative drug Lucitanib for patients with thymic cancer completed the enrollment of the first patient in China
September 2018
Haihe reached strategic cooperation agreements with Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tigermed, Junshi Biosciences, 3D Medicines, and Jiuzhou Pharmaceutical
March 2018
Haihe Pharmaceutical merged with Nuomaixi Pharmaceutical to form Haihe Biopharma Co, Ltd.
.png)
.png)
